AtriCure (ATRC) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
AtriCure Reports First Quarter 2016 Financial Results
April 28, 2016 4:08 PM EDTRevenue of $35.9 million up 20.3% as reported, 20.4% constant currency U.S. sales of $28.3 million up 23.3% International sales of $7.7 million up 10.1% as reported, 10.9% constant currency
MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced first quarter 2016 financial results.
We are pleased to report first quarter results which reflect solid operational and commercial execution. Performance in the quarter was again marked by continued growth from U.S.... More
